Table 5.
CRS as a predictor of clinical outcomes in patients with percutaneous renal revascularization
| Outcome | AUC | Sensitivity | Specificity | PPV | NPV |
|---|---|---|---|---|---|
| Hypertension benefit | |||||
| All ARAS (n = 44) | 0.720 | 66 (25/38) | 100 (6/6) | 100 (25/25) | 32 (6/19) |
| ARAS ≤70 (n = 31) | 0.786 | 54 (15/28) | 100 (3/3) | 100 (15/15) | 19 (3/16) |
| ARAS >70 (n = 13) | 1.000 | 100 (10/10) | 100 (3/3) | 100 (10/10) | 100 (3/3) |
| Renal functional benefit | |||||
| All ARAS (n = 44) | 0.803 | 71 (24/34) | 90 (9/10) | 96 (24/25) | 47 (9/19) |
| ARAS ≤70 (n = 31) | 0.642 | 58 (14/24) | 86 (6/7) | 93 (14/15) | 38 (6/16) |
| ARAS >70 (n = 13) | 1.000 | 100 (10/10) | 100 (3/3) | 100 (10/10) | 100 (3/3) |
| Both hypertension and renal functional benefit | |||||
| All ARAS (n = 44) | 0.833 | 75 (24/32) | 92 (11/12) | 96 (24/25) | 58 (11/19) |
| ARAS ≤70 (n = 31) | 0.720 | 64 (14/22) | 89 (8/9) | 93 (14/15) | 50 (8/16) |
| ARAS >70 (n = 13) | 1.000 | 100 (10/10) | 100 (3/3) | 100 (10/10) | 100 (3/3) |
Abbreviations: ARAS, atherosclerotic renal artery stenosis; AUC, area under the curve; CRS, captopril renal scintigraphy; NPV, negative predictive value; PPV, positive predictive value.